Therapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Stevens, Natalie E ^a   Chapman, Marianne J ^b,c   Fraser, Cara K ^d   Kuchel, Tim R ^d   Hayball, John D ^a,e   Diener, Kerrilyn R ^a,e  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN;

AGED; ANIMAL; BLOOD; C57BL MOUSE; CECUM; COHORT ANALYSIS; DENDRITIC CELL; DISEASE MODEL; ENDOTOXEMIA; FEMALE; HUMAN; INFLAMMATION; LIGATION; MACROPHAGE; MALE; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PHYSIOLOGY; PSEUDOMONAS AERUGINOSA; PUNCTURE; SEPSIS; SEPTIC SHOCK; SHEEP; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGED; ANIMALS; CECUM; COHORT STUDIES; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; ENDOTOXEMIA; FEMALE; HMGB1 PROTEIN; HUMANS; INFLAMMATION; LIGATION; MACROPHAGES; MALE; MICE, INBRED C57BL; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PSEUDOMONAS AERUGINOSA; PUNCTURES; SEPSIS; SHEEP; SHOCK, SEPTIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85025124336     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-06205-z     Document Type: Article

References (53)

1. Fleischmann, C. et al. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis-Current Estimates and Limitations. Am J Respir Crit Care Med 193, 259-272 (2015).
2. Ward, N. S., Casserly, B. & Ayala, A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med 29, 617-625, viii (2008).
3. Osuchowski, M. F., Craciun, F., Weixelbaumer, K. M., Duffy, E. R. & Remick, D. G. Sepsis chronically in MARS: systemic cytokine responses are always mixed regardless of the outcome, magnitude, or phase of sepsis. J Immunol 189, 4648-4656 (2012).
4. Marini, J. J., Vincent, J. L. & Annane, D. Critical care evidence-new directions. JAMA 313, 893-894 (2015).
5. Walley, K. R., Lukacs, N. W., Standiford, T. J., Strieter, R. M. & Kunkel, S. L. Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun 64, 4733-4738 (1996).
6. Surbatovic, M. et al. Cytokine profile in severe gram-positive and gram-negative abdominal sepsis. Scientific Reports 5, 11355 (2015).
7. Lv, S. et al. Anti-TNF-alpha therapy for patients with sepsis: a systematic meta-analysis. Int. J. Clin. Pract. 68, 520-528 (2014).
8. Opal, S. M. et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit. Care Med. 25, 1115-1124 (1997).
9. Manley, M. O., O'Riordan, M. A., Levine, A. D. & Latifi, S. Q. Interleukin 10 extends the effectiveness of standard therapy during late sepsis with serum interleukin 6 levels predicting outcome. Shock 23, 521-526 (2005).
10. Steinhauser, M. L. et al. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol 162, 392-399 (1999).
11. Diener, K. R., Al-Dasooqi, N., Lousberg, E. L. & Hayball, J. D. The multifunctional alarmin HMGB1 with roles in the pathophysiology of sepsis and cancer. Immunol Cell Biol 91, 443-450 (2013).
12. Yang, H. et al. Reversing established sepsis with antagonists of endogenous high-mobility group box. Proc Natl Acad Sci USA 101, 296-301 (2004).
13. Puneet, P. et al. SphK1 regulates proinflammatory responses associated with endotoxin and polymicrobial sepsis. Science 328, 1290-1294 (2010).
14. Wang, H., Yang, H., Czura, C. J., Sama, A. E. & Tracey, K. J. HMGB1 as a Late Mediator of Lethal Systemic Inflammation. American Journal of Respiratory and Critical Care Medicine 164, 1768-1773 (2001).
15. Andersson, U. & Tracey, K. J. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 29, 139-162 (2011).
16. Urbonaviciute, V. et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 205, 3007-3018 (2008).
17. Schiller, M. et al. During apoptosis HMGB1 is translocated into apoptotic cell-derived membranous vesicles. Autoimmunity 46, 342-346 (2013).
18. Venereau, E. et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 209, 1519-1528 (2012).
19. Yang, H. et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 107, 11942-11947 (2010).
20. Gong, W. et al. The anti-inflammatory activity of HMGB1 A box is enhanced when fused with C-terminal acidic tail. J Biomed Biotechnol 2010, 915234 (2010).
21. LeBlanc, P. M. et al. An immunogenic peptide in the A-box of HMGB1 protein reverses apoptosis-induced tolerance through RAGE receptor. J Biol Chem 289, 7777-7786 (2014).
22. Wild, C. A. et al. HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells. Int Immunol 24, 485-494 (2012).
23. Sunden-Cullberg, J. et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Critical Care Medicine 33, 564-573 (2005).
24. Kleiner, G., Marcuzzi, A., Zanin, V., Monasta, L. & Zauli, G. Cytokine levels in the serum of healthy subjects. Mediators of inflammation 2013, 434010 (2013).
25. Qiu, P. et al. The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death. Expert Opin Investig Drugs 20, 1555-1564 (2011).
26. Lakhan, N., Stevens, N. E., Diener, K. R. & Hayball, J. D. CoVaccine HT adjuvant is superior to Freund's adjuvants in eliciting antibodies against the endogenous alarmin HMGB1. J. Immunol. Methods (2016).
27. Dejager, L., Pinheiro, I., Dejonckheere, E. & Libert, C. Cecal ligation and puncture: the gold standard model for polymicrobial sepsis? Trends Microbiol 19, 198-208 (2011).
28. Ghosn, E. E. et al. Two physically, functionally, and developmentally distinct peritoneal macrophage subsets. Proc Natl Acad Sci USA 107, 2568-2573 (2010).
29. Cassado Ados, A. et al. Cellular renewal and improvement of local cell effector activity in peritoneal cavity in response to infectious stimuli. PLoS One 6, e22141 (2011).
30. Huang, X. et al. Neutrophils regulate humoral autoimmunity by restricting interferon-gamma production via the generation of reactive oxygen species. Cell Rep 12, 1120-1132 (2015).
31. Charoensup, J. et al. High HMGB1 level is associated with poor outcome of septicemic melioidosis. Int. J. Infect. Dis. 28, 111-116 (2016).
32. Yu, H. et al. Prognostic Value of Dynamic Monitoring of Cellular Immunity and HMGB1 in Severe Sepsis: Delayed Chronic Inflammation may be the Leading Cause of Death in Late Severe Sepsis. Clin. Lab. 62, 2379-2385 (2016).
33. Gamez-Diaz, L. Y. et al. Diagnostic accuracy of HMGB-1, sTREM-1, and CD64 as markers of sepsis in patients recently admitted to the emergency department. Acad. Emerg. Med. 18, 807-815 (2011).
34. Gaini, S., Pedersen, S. S., Koldkjaer, O. G., Pedersen, C. & Moller, H. J. High mobility group box-1 protein in patients with suspected community-acquired infections and sepsis: a prospective study. Crit Care 11, R32 (2007).
35. Karlsson, S. et al. HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med. 34, 1046-1053 (2008).
36. Suarez-Santamaria, M. et al. Prognostic value of inflammatory markers (notably cytokines and procalcitonin), nutritional assessment, and organ function in patients with sepsis. European Cytokine Network 21, 19-26 (2010).
37. Xiao, Z. et al. Inflammatory mediators in intra-abdominal sepsis or injury - a scoping review. Crit Care 19, 373 (2015).
38. Torpy, D. J., Bornstein, S. R. & Chrousos, G. P. Leptin and interleukin-6 in sepsis. Hormone and Metabolic Research 30, 726-729 (1998).
39. Oda, S. et al. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine 29, 169-175 (2005).
40. Wang, H., Zhu, S., Zhou, R., Li, W. & Sama, A. E. Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Reviews in Molecular Medicine 10, e32 (2008).
41. Ulloa, L. et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 99, 12351-12356 (2002).
42. Muenzer, J. T. et al. Pneumonia after cecal ligation and puncture: a clinically relevant "two-hit" model of sepsis. Shock 26, 565-570 (2006).
43. Theodorakis, E., Diamantaki, E., Tsatsanis, C., Georgopoulos, D. & Vaporidi, K. Macrophage phenotype in sepsis immunosuppression. Critical Care 19, P44-P44 (2015).
44. Fan, X., Liu, Z., Jin, H., Yan, J. & Liang, H. P. Alterations of dendritic cells in sepsis: featured role in immunoparalysis. BioMed Research International 2015, 903720 (2015).
45. Wen, H., Dou, Y., Hogaboam, C. M. & Kunkel, S. L. Epigenetic regulation of dendritic cell-derived interleukin-12 facilitates immunosuppression after a severe innate immune response. Blood 111, 1797-1804 (2008).
46. Aneja, R. K. et al. Preconditioning with high mobility group box 1 (HMGB1) induces lipopolysaccharide (LPS) tolerance. J Leukoc Biol 84, 1326-1334 (2008).
47. Pene, F. et al. Dendritic cells modulate lung response to Pseudomonas aeruginosa in a murine model of sepsis-induced immune dysfunction. J Immunol 181, 8513-8520 (2008).
48. Dumitriu, I. E., Bianchi, M. E., Bacci, M., Manfredi, A. A. & Rovere-Querini, P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 81, 84-91 (2007).
49. Zhang, L. T. et al. Association between high-mobility group box-1 protein release and immune function of dendritic cells in thermal injury. Journal of Interferon and Cytokine Research 30, 487-495 (2010).
50. Marshall, J. C. Why have clinical trials in sepsis failed? Trends in Molecular Medicine 20, 195-203 (2014).
51. Reddi, B. A., Beltrame, J. F., Young, R. L. & Wilson, D. P. Calcium desensitisation in late polymicrobial sepsis is associated with loss of vasopressor sensitivity in a murine model. Intensive Care Med Exp 3, 36 (2015).
52. Gogos, C. A., Drosou, E., Bassaris, H. P. & Skoutelis, A. Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 181, 176-180 (2000).
53. Bozza, F. A. et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 11, R49 (2007).